|371.96||+10.84||+3.00%||Vol 60.19K||1Y Perf -22.12%|
|Aug 10th, 2022 13:04 DELAYED|
|- -%||- -|
|Target Price||507.14||Analyst Rating||Moderate Buy 1.67|
|Potential %||36.34||Finscreener Ranking||★★★ 48.79|
|Insiders Trans % 3/6/12 mo.||-50/-50/-97||Value Ranking||★+ 43.70|
|Insiders Value % 3/6/12 mo.||-92/-92/-100||Growth Ranking||★★★★★ 73.16|
|Insiders Shares Cnt. % 3/6/12 mo.||-91/-91/-100||Income Ranking||★+ 36.95|
|Price Range Ratio 52W %||23.87||Earnings Rating||Buy|
|Market Cap||14.59B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||1.86|
|EPS Growth Next 5 Years %||26.00|
|Avg. Weekly Volume||271.74K|
|Avg. Monthly Volume||206.31K|
|Avg. Quarterly Volume||225.14K|
Bio-Techne Corp (NASDAQ: TECH) stock closed at 361.12 per share at the end of the most recent trading day (a -3.74% change compared to the prior day closing price) with a volume of 301.86K shares and market capitalization of 14.59B. Is a component of S&P 500, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 2600 people. Bio-Techne Corp CEO is Charles R. Kummeth.
The one-year performance of Bio-Techne Corp stock is -22.12%, while year-to-date (YTD) performance is -30.2%. TECH stock has a five-year performance of 209.31%. Its 52-week range is between 318.07 and 543.85, which gives TECH stock a 52-week price range ratio of 23.87%
Bio-Techne Corp currently has a PE ratio of 63.00, a price-to-book (PB) ratio of 7.88, a price-to-sale (PS) ratio of 16.14, a price to cashflow ratio of 41.00, a PEG ratio of 2.32, a ROA of 10.56%, a ROC of 12.19% and a ROE of 14.23%. The company’s profit margin is 24.61%, its EBITDA margin is 31.70%, and its revenue ttm is $817.37 Million , which makes it $20.83 revenue per share.
Of the last four earnings reports from Bio-Techne Corp, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.86 for the next earnings report. Bio-Techne Corp’s next earnings report date is -.
The consensus rating of Wall Street analysts for Bio-Techne Corp is Moderate Buy (1.67), with a target price of $507.14, which is +36.34% compared to the current price. The earnings rating for Bio-Techne Corp stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Bio-Techne Corp has a dividend yield of 0.38% with a dividend per share of $1.28 and a payout ratio of 27.00%.
Bio-Techne Corp has a Sell technical analysis rating based on Technical Indicators (ADX : 12.81, ATR14 : 14.09, CCI20 : -11.18, Chaikin Money Flow : 0.27, MACD : 6.31, Money Flow Index : 56.29, ROC : -0.59, RSI : 39.00, STOCH (14,3) : 9.56, STOCH RSI : 0.00, UO : 52.71, Williams %R : -90.44), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Bio-Techne Corp in the last 12-months were: Brenda S. Furlow (Option Excercise at a value of $1 961 499), Brenda S. Furlow (Sold 15 409 shares of value $7 708 924 ), Charles R. Kummeth (Option Excercise at a value of $19 170 783), Charles R. Kummeth (Sold 5 104 shares of value $1 862 960 ), David Eansor (Option Excercise at a value of $3 496 148), David Eansor (Sold 28 697 shares of value $14 461 920 ), James T. Hippel (Option Excercise at a value of $2 276 884), James T. Hippel (Sold 19 784 shares of value $10 222 375 ), John L. Higgins (Option Excercise at a value of $107 040), John L. Higgins (Sold 1 600 shares of value $583 964 ), Kim Kelderman (Option Excercise at a value of $375 291), Kim Kelderman (Sold 1 322 shares of value $687 560 ), N. David Eansor (Option Excercise at a value of $3 496 148), N. David Eansor (Sold 28 697 shares of value $14 461 920 ), Randolph C. Steer (Option Excercise at a value of $349 560), Randolph C. Steer (Sold 8 000 shares of value $4 079 822 ), Robert V. Baumgartner (Buy at a value of $105 765), Robert V. Baumgartner (Option Excercise at a value of $349 560), Robert V. Baumgartner (Sold 4 000 shares of value $1 942 183 ), Roeland Nusse (Option Excercise at a value of $562 800), Roeland Nusse (Sold 8 000 shares of value $3 852 128 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.